Stereotaxis (STXS) Debt to Equity (2010 - 2026)

Stereotaxis (STXS) reported Debt to Equity of $0.37 for Q1 2026, up 1.03% quarter-over-quarter from $0.36 in Q4 2025.

Stereotaxis (STXS) Debt to Equity (2010 - 2026) Analysis & Trends

Stereotaxis (STXS) has 12 years of Debt to Equity data on file, last reported at $0.37 in Q1 2026.

Debt to Equity for Q1 2026 came in at $0.37, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $0.37 (changed N/A YoY), and the FY2025 annual result was $0.36, down 60.85% from the prior year.
Debt to Equity advanced to $0.37 in Q1 2026 per STXS's latest filing, from $0.36 in the prior quarter.
Over five years, Debt to Equity peaked at $0.93 in Q4 2024 and troughed at $0.36 in Q4 2025.
A 3-year average of $0.64 and a median of $0.63 in 2025 frame the typical range for Debt to Equity.
On a YoY basis, Debt to Equity climbed as much as 60.85% in 2025 and fell as far as 60.85% in 2025.
A 3-year view of Debt to Equity shows it stood at $0.93 in 2024, then plunged by 60.85% to $0.36 in 2025, then grew by 1.03% to $0.37 in 2026.
Business Quant data shows STXS's Debt to Equity at $0.37 in Q1 2026, $0.36 in Q4 2025, and $0.89 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Intuitive Surgical	148.09 Bn	143.69 Bn	1.83 Bn	-
2	Becton Dickinson	41.00 Bn	39.99 Bn	2.15 Bn	0.72
3	Medline	30.38 Bn	36.22 Bn	1.84 Bn	1.12
4	Resmed	28.22 Bn	26.56 Bn	890.98 Mn	0.04
5	West Pharmaceutical Services	23.72 Bn	23.19 Bn	296.40 Mn	0.07
6	Solventum	13.33 Bn	13.33 Bn	1.10 Bn	1.02
7	Cooper Companies	13.12 Bn	12.99 Bn	735.40 Mn	0.30
8	Align Technology	12.86 Bn	11.80 Bn	736.59 Mn	-
9	Baxter International	10.51 Bn	8.47 Bn	891.00 Mn	1.57
10	Stereotaxis	180.48 Mn	165.86 Mn	3.79 Mn	0.37

Download Data